Singapore Markets close in 4 hrs 47 mins
  • Straits Times Index

    -0.09 (-0.00%)
  • Nikkei

    -84.85 (-0.31%)
  • Hang Seng

    -41.38 (-0.21%)
  • FTSE 100

    -67.24 (-0.89%)

    +851.70 (+3.11%)
  • CMC Crypto 200

    +20.96 (+3.51%)
  • S&P 500

    +11.75 (+0.30%)
  • Dow

    +75.14 (+0.23%)
  • Nasdaq

    +117.44 (+1.01%)
  • Gold

    -0.60 (-0.03%)
  • Crude Oil

    -0.23 (-0.33%)
  • 10-Yr Bond

    -0.0940 (-2.69%)
  • FTSE Bursa Malaysia

    -6.74 (-0.48%)
  • Jakarta Composite Index

    +69.45 (+1.04%)
  • PSE Index

    +32.97 (+0.50%)

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $72.45, moving -0.74% from the previous trading session. This move lagged the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.08%, while the tech-heavy Nasdaq added 7.26%.

Coming into today, shares of the biopharmaceutical company had gained 1.23% in the past month. In that same time, the Medical sector lost 0.75%, while the S&P 500 gained 5.73%.

Investors will be hoping for strength from Bristol Myers Squibb as it approaches its next earnings release, which is expected to be February 2, 2023. On that day, Bristol Myers Squibb is projected to report earnings of $1.72 per share, which would represent a year-over-year decline of 6.01%. Our most recent consensus estimate is calling for quarterly revenue of $11.13 billion, down 7.12% from the year-ago period.

Investors should also note any recent changes to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).

Digging into valuation, Bristol Myers Squibb currently has a Forward P/E ratio of 9.24. This valuation marks a discount compared to its industry's average Forward P/E of 20.75.

Investors should also note that BMY has a PEG ratio of 1.63 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.63 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research